Cytokinetics 将来の成長

Future 基準チェック /26

Cytokineticsは、35.1%と68.2%でそれぞれ年率35.1%で利益と収益が成長すると予測される一方、EPSはgrowで37.9%年率。

主要情報

35.1%

収益成長率

37.9%

EPS成長率

Biotechs 収益成長	27.3%
収益成長率	68.2%
将来の株主資本利益率	n/a
アナリストカバレッジ	Good
最終更新日	12 Nov 2024

今後の成長に関する最新情報

Recent updates

Here's Why We Think Cytokinetics, Incorporated's (NASDAQ:CYTK) CEO Compensation Looks Fair for the time being

May 09

Cytokinetics, Incorporated: Buyout Speculation Persists

Apr 01

Cytokinetics: CEO Talks Down Buyout Prospects

Mar 16

Cytokinetics Steps Up As Prime Target After Aficamten's HCM Triumph (Rating Upgrade)

Jan 12

An Intrinsic Calculation For Cytokinetics, Incorporated (NASDAQ:CYTK) Suggests It's 37% Undervalued

Oct 05

業績と収益の成長予測

NasdaqGS:CYTK - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	315	-483	-522	-409	13
12/31/2025	47	-623	-636	-529	15
12/31/2024	9	-592	-428	-455	16
9/30/2024	3	-576	-407	-404	N/A
6/30/2024	3	-545	-401	-399	N/A
3/31/2024	4	-531	-423	-422	N/A
12/31/2023	8	-526	-416	-414	N/A
9/30/2023	8	-527	-443	-438	N/A
6/30/2023	10	-540	-437	-426	N/A
3/31/2023	98	-431	-406	-395	N/A
12/31/2022	95	-389	-311	-300	N/A
9/30/2022	148	-282	-272	-246	N/A
6/30/2022	151	-216	-236	-201	N/A
3/31/2022	65	-258	-183	-140	N/A
12/31/2021	70	-215	-191	-143	N/A
9/30/2021	22	-229	-83	-46	N/A
6/30/2021	58	-156	-17	8	N/A
3/31/2021	59	-135	-7	10	N/A
12/31/2020	56	-127	-2	9	N/A
9/30/2020	54	-114	-68	-62	N/A
6/30/2020	19	-140	-101	-97	N/A
3/31/2020	22	-132	-98	-94	N/A
12/31/2019	27	-122	-94	-91	N/A
9/30/2019	31	-118	-86	-84	N/A
6/30/2019	36	-110	-97	-96	N/A
3/31/2019	35	-105	-99	-98	N/A
12/31/2018	32	-106	-102	-101	N/A
9/30/2018	22	-120	-114	-113	N/A
6/30/2018	18	-131	N/A	-106	N/A
3/31/2018	14	-132	N/A	-111	N/A
12/31/2017	13	-128	N/A	-102	N/A
9/30/2017	47	-80	N/A	0	N/A
6/30/2017	99	-14	N/A	14	N/A
3/31/2017	102	3	N/A	34	N/A
12/31/2016	106	16	N/A	37	N/A
9/30/2016	83	0	N/A	-51	N/A
6/30/2016	32	-42	N/A	-49	N/A
3/31/2016	33	-41	N/A	-47	N/A
12/31/2015	29	-38	N/A	5	N/A
9/30/2015	41	-20	N/A	7	N/A
6/30/2015	42	-17	N/A	8	N/A
3/31/2015	43	-15	N/A	7	N/A
12/31/2014	47	-15	N/A	-45	N/A
9/30/2014	50	-17	N/A	-49	N/A
6/30/2014	45	-23	N/A	-29	N/A
3/31/2014	38	-30	N/A	-13	N/A
12/31/2013	31	-34	N/A	-8	N/A

アナリストによる今後の成長予測

収入対貯蓄率: CYTK今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CYTK今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: CYTK今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CYTKの収益 ( 68.2% ) US市場 ( 8.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: CYTKの収益 ( 68.2% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: CYTKの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Cytokinetics 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Consensus revenue estimates decrease by 23%

Consensus revenue estimates fall by 54%

Consensus revenue estimates increase by 10%

Price target decreased by 7.5% to US$86.06

Consensus revenue estimates increase by 41%

Consensus revenue estimates decrease by 13%

Recent updates

Cytokinetics, Incorporated Announces Initiation of Phase 1 Clinical Study of CK-4015089

Now 20% overvalued after recent price rise

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Insider notifies of intention to sell stock

Cytokinetics, Incorporated to Report Q3, 2024 Results on Nov 06, 2024

Insider notifies of intention to sell stock

Cytokinetics Presents Additional Data from EQUOIA-HCM At the HCMS Scientific Sessions

Consensus revenue estimates decrease by 23%

Cytokinetics, Incorporated Presents Additional Data from SEQUOIA-HCM at the European Society of Cardiology Congress 2024

Insider notifies of intention to sell stock

Consensus revenue estimates fall by 54%

CEO, President & Director notifies of intention to sell stock

Cytokinetics: Aficamten Rolling NDA Submission Leads To Expansion Opportunities

Is Cytokinetics (NASDAQ:CYTK) Weighed On By Its Debt Load?

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

CEO, President & Director notifies of intention to sell stock

Cytokinetics, Incorporated to Report Q2, 2024 Results on Aug 08, 2024

Cytokinetics' Aficamten: Heartfelt Potential Amid Market Woes

CEO, President & Director recently sold US$622k worth of stock

Consensus revenue estimates increase by 10%

CEO, President & Director recently sold US$1.2m worth of stock

Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants

CEO, President & Director notifies of intention to sell stock

VP & Chief Accounting Officer recently sold US$636k worth of stock

New minor risk - Insider selling

Cytokinetics, Incorporated announced that it has received $49.999992 million in funding from Royalty Pharma Development Funding, LLC

Price target decreased by 7.5% to US$86.06

Consensus revenue estimates increase by 41%

Cytokinetics Decides To Go It Alone

Cytokinetics, Incorporated has completed a Follow-on Equity Offering in the amount of $500.000022 million.

Consensus revenue estimates decrease by 13%

Cytokinetics, Incorporated Announces Resignation of Sandford D. Smith as Board of Directors

Insider notifies of intention to sell stock

Here's Why We Think Cytokinetics, Incorporated's (NASDAQ:CYTK) CEO Compensation Looks Fair for the time being

Cytokinetics, Incorporated Announces CEDAR-HCM Is Open to Enrollment

Consensus revenue estimates decrease by 12%

Independent Chairman notifies of intention to sell stock

Cytokinetics, Incorporated Appoints Sung H. Lee as Executive Vice President, Effective as of May 8, 2024

Cytokinetics, Incorporated to Report Q1, 2024 Results on May 08, 2024

Insider exercised options and sold US$1.9m worth of stock

Cytokinetics, Incorporated, Annual General Meeting, May 15, 2024

Cytokinetics Presents Additional 48-Week Data from Forest-Hcm, the Open Label Extension Clinical Study of Aficamten, At the American College of Cardiology 73rd Annual Scientific Session

Cytokinetics, Incorporated: Buyout Speculation Persists

Cytokinetics: CEO Talks Down Buyout Prospects

Insider notifies of intention to sell stock

Consensus revenue estimates decrease by 49%, EPS upgraded

Cytokinetics, Incorporated Provides Revenue Guidance for 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Cytokinetics, Incorporated to Report Q4, 2023 Results on Feb 27, 2024

Cytokinetics, Incorporated Announces Resignation of Ching W. Jaw as Chief Financial Officer, Effective February 23, 2024

Cytokinetics, Incorporated Announces Resignation of Ching W. Jaw as Chief Financial Officer, Effective February 23, 2024

Cytokinetics, Incorporated Announces Resignation of Ching W. Jaw, Senior Vice President, Effective February 23, 2024

CEO, President & Director notifies of intention to sell stock

CEO, President & Director notifies of intention to sell stock

Novartis Pursuit of Cytokinetics Reportedly Cools

Novartis Pursuit of Cytokinetics Reportedly Cools

Cytokinetics Steps Up As Prime Target After Aficamten's HCM Triumph (Rating Upgrade)

Novartis Reportedly in Advanced Talks to Buy Cytokinetics

Novartis Reportedly in Advanced Talks to Buy Cytokinetics

CEO, President & Director notifies of intention to sell stock

Cytokinetics, Incorporated Announces Positive Results from Sequoia-Hcm, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy

New major risk - Revenue and earnings growth

Price target increased by 20% to US$74.39

CEO, President & Director notifies of intention to sell stock

Cytokinetics Presents Results from COURAGE-ALS At the 34th International Symposium on ALS/MND

Now 23% undervalued after recent price drop

CEO, President & Director exercised options and sold US$329k worth of stock

Insufficient new directors

CEO, President & Director notifies of intention to sell stock